|
CALENDAR OF EVENTS |
Investor Conferences and Events
|
May 5, 2008
|
|
|
|
|
May 7, 2008
|
HGS Annual Meeting of Shareholders
|
Rockville, MD
|
|
|
May 21, 2008
|
Citigroup Healthcare Conference
|
New York, NY
|
|
|
May 28, 2008
|
HGS Analyst & Investor Meeting
|
New York, NY
|
|
|
Jun 10, 2008
|
Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
|
Laguna Niguel, CA
|
|
|
Sep 3-5, 2008
|
Thomas Weisel Partners Annual Healthcare Conference
|
Boston, MA
|
|
Scientific Conferences
|
May 8-10, 2008
|
LUPUS 08 – 7th European Lupus Meeting
Correlation of Biomarker Changes with Clinical Improvement Over 2.5 Years of Belimumab (Fully Human Monoclonal Antibody to BLyS) Therapy in Systemic Lupus Erythematosus ( SLE ) Patients - Oral presentation - May 9, 2008
Belimumab (Fully Human Monoclonal Antibody to BLyS) Improved or Stabilized Systemic Lupus Erythematosus (SLE) Disease Activity Over 2.5 Years of Therapy - Oral presentation, May 9, 2008
Long-Term Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in Patients with Systemic Lupus Erythematosus (SLE) - Poster presentation, May 8, 2008
Improvement in Valvular Heart Disease in a Systemic Lupus Erythematosus ( SLE ) Patient Treated with Belimumab Fully Human Monoclonal Antibody to BLyS): Case Report - Poster presentation, May 9, 2008
|
Amsterdam, Netherlands
|
|
|
May 17-22, 2008
|
2008 Digestive Disease Week
Viral Kinetics and Pharmacodynamics of Albinterferon Alfa-2b in Interferon Treatment-Naïve Patients with Genotype 1, Chronic Hepatitis C Poster Presentation, May 18, 2008
Health-Related Quality of Life (HRQOL) With Albinterferon Alfa-2b Plus Ribavirin in IFN Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Poster Presentation, May 18, 2008
|
San Diego, California
|
|
|
Jun 11-14, 2008
|
EULAR Congress 2008
Belimumab (Fully Human Monoclonal Antibody to BLyS) Reduced Steroid Use in Systemic Lupus Erythematosus (SLE) Patients During 3 Years of Therapy Poster Presentation June 12, 2008
Belimumab (Fully Human Monoclonal Antibody to BLyS) Improved or Stabilized Systemic Lupus Erythematosus (SLE) Disease Activity and Reduced Flare Rate During 3 Years of Therapy Oral Presentation June 12, 2008
Progressive Normalization of Autoantibody, Immunoglobulin, and Complement Levels Over 3 Years of Belimumab (Fully Human Monoclonal Antibody to BLyS) Therapy in Systemic Lupus Erythematosus (SLE) Patients Poster Presentation June 12, 2008
Long-Term Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in Patients with Systemic Lupus Erythematosus (SLE) Poster Presentation June 12, 2008
|
Paris, France
|
|
|
| |
|
|
